Comparison of blood dynamics of anticancer drugs (cisplatin, mitomycin C, epirubicin) in treatment groups of hepatic arterial infusion, hepatic arterial infusion with lipiodol and transcatheter arterial chemoembolization with lipiodol plus gelatin sponge particles in a swine model

被引:6
作者
Ikoma, Akira [1 ]
Kawai, Nobuyuki [1 ]
Sato, Morio [1 ]
Minamiguchi, Hiroki [1 ]
Nakai, Motoki [1 ]
Nakata, Kouhei [1 ]
Tanaka, Takami [1 ]
Sonomura, Tetsuo [1 ]
机构
[1] Wakayama Med Univ, Dept Radiol, Wakayama 6418510, Japan
关键词
hepatic arterial infusion; lipiodol; liver damage; transcatheter arterial chemoembolization; UNRESECTABLE HEPATOCELLULAR-CARCINOMA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; EMBOLIZATION; LIVER; CHEMOTHERAPY; AGENTS; CANCER; TUMORS; RAT;
D O I
10.1111/j.1872-034X.2012.01040.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: To compare the blood dynamics of anticancer drugs (cisplatin, mitomycin, epirubicin) and the negative effect on normal liver tissue among the following procedures: hepatic arterial infusion (HAI), HAI with lipiodol (Lp-HAI) and transcatheter arterial chemoembolization (TACE) with Lp plus particles (Lp-TACE). Methods: Nine swine were divided into three groups: (i) HAI group animals were infused with 5 mg/mL cisplatin, 1 mg/mL mitomycin and 4 mg/mL epirubicin in 0.1 mL/kg contrast medium; (ii) Lp-HAI group animals, with the same doses in 0.1 mL emulsified fluid (0.05 mL/kg, Lp); and (iii) Lp-TACE group animals, with the same doses in 0.1 mL emulsified fluid plus gelatin sponge particles. Outflow ratio (area under plasma concentration curve [AUC060] / total infused dose of anticancer drug) and necrosis volume ratio (necrosis volume / total slice volume x 100) were explored. Results: Outflow ratios (AUC060/mg) of cisplatin, mitomycin and epirubicin, and the necrosis volume ratio (%) of the livers, were 2.30, 6.91, 0.97 and 0, respectively, in the HAI group; 1.71, 5.43, 0.79 and 1.37, respectively, in the Lp-HAI group; and 1.23, 3.37, 0.47 and 20.88, respectively, in the Lp-TACE group. The significantly lowest outflow ratio for each anticancer drug (P = 0.05/3) and the significantly highest necrosis volume ratio (P = 0.05/3) were found in Lp-TACE, followed by Lp-HAI and HAI. Conclusion: Although the necrosis volume ratio of the liver was tolerable, Lp-TACE caused the greatest delay in outflow ratio for each cancer drug and the greatest negative effect to liver in a swine model.
引用
收藏
页码:1227 / 1235
页数:9
相关论文
共 24 条
  • [1] DRUGS 10 YEARS LATER - EPIRUBICIN
    BONADONNA, G
    GIANNI, L
    SANTORO, A
    BONFANTE, V
    BIDOLI, P
    CASALI, P
    DEMICHELI, R
    VALAGUSSA, P
    [J]. ANNALS OF ONCOLOGY, 1993, 4 (05) : 359 - 369
  • [2] Hepatic arterial chemoembolization for hepatocellular carcinoma: Comparison of survival rates with different embolic agents
    Brown, DB
    Pilgram, TK
    Darcy, MD
    Fundakowski, CE
    Lisker-Melman, M
    Chapman, WC
    Crippin, JS
    [J]. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2005, 16 (12) : 1661 - 1666
  • [3] Triple-Drug Transcatheter Arterial Chemoembolization in Unresectable Hepatocellular Carcinoma: Assessment of Survival in 124 Consecutive Patients
    Gomes, Antoinette S.
    Rosove, Michael H.
    Rosen, Peter J.
    Amado, Rafael G.
    Sayre, James W.
    Monteleone, Phillip A.
    Busuttil, Ronald W.
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2009, 193 (06) : 1665 - 1671
  • [4] SELECTIVE EFFECTS OF LIPIODOLIZED ANTITUMOR AGENTS
    KANEMATSU, T
    INOKUCHI, K
    SUGIMACHI, K
    FURUTA, T
    SONODA, T
    TAMURA, S
    HASUO, K
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 1984, 25 (03) : 218 - 226
  • [5] Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:: a randomised controlled trial
    Llovet, JM
    Real, MI
    Montaña, X
    Planas, R
    Coll, S
    Aponte, J
    Ayuso, C
    Sala, M
    Muchart, J
    Solà, R
    Rodés, J
    Bruix, J
    [J]. LANCET, 2002, 359 (9319) : 1734 - 1739
  • [6] Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
    Lo, CM
    Ngan, H
    Tso, WK
    Liu, CL
    Lam, CM
    Poon, RTP
    Fan, ST
    Wong, J
    [J]. HEPATOLOGY, 2002, 35 (05) : 1164 - 1171
  • [7] Masuda M, 2002, J WAKAYAMA MED SOC, V53, P185
  • [8] Effect of acute hepatic failure on epirubicin pharmacokinetics after intrahepatic arterial injection in rats
    Nagata, Masashl
    Matsuo, Yasuko
    Hidaka, Muneakl
    Kawano, Yohei
    Okumura, Manabu
    Tokunaga, Jin
    Takamura, Norito
    Arimori, Kazuhlko
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2008, 31 (03) : 493 - 496
  • [9] NAKAKUMA K, 1983, CANCER-AM CANCER SOC, V52, P2193, DOI 10.1002/1097-0142(19831215)52:12<2193::AID-CNCR2820521203>3.0.CO
  • [10] 2-R